What do systematic reviews say?

Weight gain · people with psychosis

Weight gain (equal or greater then 7% of baseline) · people with psychosis

High prolactin at any time during treatment · people with psychosis

Change in corrected QT · people with psychosis

Use of other antipsychotics · people with psychosis

No improvement (clozapine vs olanzapine) · people with psychosis

Drug‐induced diabetes (clozapine vs olanzapine) · people with psychosis

Elevated prolactin (risperidone vs quetiapine) · people with psychosis

Weight gain · people with psychosis

Leaving the study early because of weight gain (risperidone vs olanzapine) · people with psychosis

No improvement (risperidone vs olanzapine) · people with psychosis

Worse or no improvement · people with psychosis

Adverse effects ‐ anticholinergic effects · people with psychosis

Drop in the absolute neutrophil count below 1500 per mm3 · people with psychosis

Adverse effects: Leaving the study early · people with psychosis

No response · people with psychosis

Symptomatic hyperprolactinaemia · people with psychosis

Use of antiparkinsonian medications · people with psychosis

Weight gain · people with psychosis

Relapse · patients with schizophrenia